Epsilon-aminocaproic acid influence in bleeding and hemotransfusion postoperative in mitral valve surgery;Influência do ácido épsilon aminocapróico no sangramento e na hemotransfusão pós-operatória em cirurgia valvar mitral

Brazilian Journal of Cardiovascular Surgery

Volumn 25, Issue 4, 2010, Pages 510-515

  Benfatti, Ricardo Adala ^a   Carli, Amanda Ferreira ^b   da Silva, Guilherme Viotto Rodrigues ^a   Dias, Amaury Edgardo Mont'serrat Ávila Souza ^a   Goldiano, José Anderson ^a   Pontes, José Carlos Dorsa Vieira ^a  

^a UFMS ^*

^b Heart Hospital HCOR   (Brazil)

Author keywords

Antifibrinolytic agents; Blood transfusion; Hemostasis

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; BLOOD VOLUME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EPIDEMIOLOGY; HUMAN; MITRAL VALVE; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

6-AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; BLOOD VOLUME; EPIDEMIOLOGIC METHODS; HUMANS; MITRAL VALVE; POSTOPERATIVE COMPLICATIONS;

EID: 79952275532     PISSN: 01027638     EISSN: 16789741     Source Type: Journal    
DOI: 10.1590/S0102-76382010000400015     Document Type: Article

References (22)

1. Pontes JCDV, Matos MFC, Medeiros CGS, Silva AF, Duarte JJ, Gardenal N, et al. Estudo comparativo do emprego da aprotinina em baixas doses X placebo, durante a circulação extracorpórea. Rev Bras Cir Cardiovasc. 2002;17(1):47-53.
2. Kirklin JW, Barrat-Boyes BG. Postoperative care. In: Kirklin JW, Barrat-Boyes BG, eds. Cardiac surgery. New York:Churchil Livingstone;1986.
3. Horrow JC. Management of coagulopathy associated with cardiopulmonary by-pass. In: Gravlee GP, Davis RF, Utley JR, eds. Cardiopulmonary bypass: principles and practice. Baltimore:Williams & Wilkins;1993.
4. Ellison N, Jobes D. Hemostasis during cardiopulmonary bypass. In: Tinker JH, ed. Cardiopulmonary bypass: current concepts and controversies. Philadelphia: W. B. Saunders; 1989.
5. Kucuk O, Kwaan HC, Frederickson J, Wade L, Green D. Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation. Am J Hematol. 1986;23(3):223-9.
6. Petterson CM, Stammers AH, Kohtz RJ, Kmiecik SA, Nichols JD, Mills NJ, et al. The effects of ultrafiltration on e- aminocaproic acid: an in vitro analysis. J Extra Corpor Technol. 2002:34(3):197-202.
7. Miana, LA, Atik FA, Moreira LF, Hueb AC, Jatene FB, Auler Junior JO, et al. Fatores de risco de sangramento no pós- operatório de cirurgia cardíaca em pacientes adultos. Rev Bras Cir Cardiovasc. 2004;19(3):280-6.
8. Harmon DE. Cost/benefit analysis of pharmacologic hemostasis. Ann Thorac Surg. 1996;61(2 Suppl):S21-5.
9. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2007;(4):CD001886.
10. Rosén M. The aprotinin saga and the risks of conducting meta- analyses on small randomised controlled trials: a critique of a Cochrane review. BMC Health Serv Res. 2009;9:34.
11. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358(22):2319-31.
12. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, O'Connor GT, Dacey LJ. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis. Circulation. 1999;99(1):81-9.
13. Elias DO, Souza MHL. Antifibrinolíticos na profilaxia do sangramento pós-perfusão: II Ácido épsilon aminocapróico. Disponível em: www.perfline.com/artigos/artigos98/epsilon.htm
14. Despotis GJ, Skubas NJ, Goodnough LT. Optimal management of bleeding and transfusion in patients undergoing cardiac surgery. Semin Thorac Cardiovasc Surg. 1999;11(2):84-104.
15. Karski JM, Dowd NP, Joiner R, Carroll J, Peniston C, Bailey K, et al. The effect of three different doses of tranexamic acid on blood loss after cardiac surgery with mild systemic hypothermia (32 degrees C). J Cardiothorac Vasc Anesth. 1988;12(6):642-6.
16. DelRossi AJ, Cernaianu AC, Botros S, Lemole GM, Moore R. Prophylactic treatment of postperfusion bleeding using EACA. Chest. 1989;96(1):27-30.
17. Montesano RM, Gustafson PA, Palanzo DA, Manley NJ, Sadr FS. The effect of low-dose epsilon-aminocaproic acid on patients following coronary artery bypass surgery. Perfusion. 1996;11(1):53-6.
18. Breda JR, Gurian DB, Breda ASCR, Meneghine A, Freitas ACO, Matos LL, et al. Uso tópico de agente antifibrinolítico na redução do sangramento após revascularização cirúrgica do miocárdio. Rev Bras Cir Cardiovasc. 2009;24(3):341-5.
19. Henry D, Carless P, Fergusson D, Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ. 2009;180(2):183-93.
20. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation. 2007;115(22):2801-13.
21. Souza HJ, Moitinho RF. Estratégias para redução do uso de hemoderivados em cirurgia cardiovascular. Rev Bras Cir Cardiovasc. 2008;23(1):53-9.
22. Royston D. Aprotinin versus lysine analogues: the debate continues. Ann Thorac Surg. 1998;65(4 Suppl):S9-19.